NCT01613768: Eribulin Mesylate in Treating Patients With Recurrent or Metastatic Salivary Gland Cancer |
|
|
| Completed | 2 | 29 | US | eribulin mesylate, B1939, E7389, ER-086526, halichrondrin B analog | University of Washington, National Cancer Institute (NCI) | Recurrent Salivary Gland Cancer, Stage IVA Salivary Gland Cancer, Stage IVB Salivary Gland Cancer, Stage IVC Salivary Gland Cancer | 08/17 | 08/17 | | |
